| 纯度 | >90%SDS-PAGE. |
| 种属 | E.coli |
| 靶点 | VB2 |
| Uniprot No | Q01225 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-219aa |
| 氨基酸序列 | MAMFYAHALGGYDENLHAFPGISSTVANDVRKYSVVSVYNNKYDIVKDKYMWCYSQVNKRYIGALLPMFECNEYLQIGDPIHDQEGNQISIITYRHKNYYALSGIGYESLDLCLEGVGIHHHVLETGNAVYGKVQHDYSTIKEKAKEMNALSPGPIIDYHVWIGDCICQVTAVDVHGKEIMRMRFKKGAVLPIPNLVKVKLGENDTENLSSTISAAPSR |
| 预测分子量 | 24,6 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于VB2(维生素B2/核黄素)重组蛋白的模拟参考文献(基于公开研究背景整理，非真实文献)：
---
1. **文献名称**：*Heterologous Expression of Riboflavin Synthase in Escherichia coli for Enhanced Vitamin B2 Production*
**作者**：Zhang Y, et al.
**摘要**：研究通过在大肠杆菌中重组表达核黄素合成酶，优化了维生素B2的体外生物合成途径，显著提高了核黄素产量，为工业化发酵生产提供了新策略。
2. **文献名称**：*Structural and Functional Analysis of Recombinant Riboflavin-Binding Protein from Chicken Egg*
**作者**：Kumar S, et al.
**摘要**：通过基因重组技术表达了鸡卵黄中的核黄素结合蛋白，解析其晶体结构并验证其与核黄素的高亲和力，为营养载体设计和核黄素递送研究奠定基础。
3. **文献名称**：*Metabolic Engineering of Bacillus subtilis for Riboflavin Production via Recombinant Pathway*
**作者**：Wang H, et al.
**摘要**：通过重组枯草芽孢杆菌的代谢途径，敲除竞争通路并过表达关键酶基因，实现核黄素的高效合成，为微生物法生产维生素B2提供理论支持。
4. **文献名称**：*Recombinant Riboflavin Transporters: Characterization and Application in Nutrient Delivery Systems*
**作者**：Müller R, et al.
**摘要**：克隆并表达了来自酵母的核黄素转运蛋白，验证其在人工膜系统中的功能，探讨其在靶向递送核黄素或药物中的应用潜力。
---
**说明**：以上为模拟文献，实际文献需通过PubMed、Web of Science或Google Scholar等平台检索关键词(如“recombinant riboflavin protein”或“vitamin B2 heterologous expression”)获取。建议结合具体研究方向筛选近5年的高质量论文。
**Background of VB2 Recombinant Protein**
VB2 recombinant protein is a biologically engineered molecule derived from the *Varicella-Zoster virus (VZV)*, specifically targeting glycoprotein B2 (gB2), a critical antigen involved in viral entry and immune evasion. As a subunit vaccine candidate, it is designed to elicit targeted immune responses against VZV, the pathogen responsible for chickenpox and shingles. Traditional live-attenuated vaccines, while effective, pose risks for immunocompromised individuals, driving demand for safer alternatives. Recombinant protein technology offers a solution by expressing purified viral antigens in heterologous systems (e.g., *E. coli*, yeast, or mammalian cells*), ensuring high specificity without viral replication risks.
The production of VB2 involves cloning the *gB2 gene* into expression vectors, followed by protein purification using chromatography techniques. Its immunogenicity is often enhanced with adjuvants (e.g., aluminum salts or newer platforms like AS01*), which promote robust T-cell and antibody responses. Preclinical studies highlight its potential to neutralize VZV and reduce viral load in animal models.
VB2 also serves as a tool for diagnostic assays, aiding in serological testing to distinguish vaccinated from naturally infected individuals. Its scalability and stability under controlled conditions make it suitable for global distribution, addressing challenges in regions with limited cold-chain infrastructure.
Despite progress, challenges remain, including optimizing antigen conformation to mimic native viral structures and ensuring long-term immunity. Ongoing research focuses on combination vaccines incorporating multiple VZV antigens (e.g., gE, gB) to broaden protection. As recombinant protein technology advances, VB2 exemplifies a shift toward safer, modular vaccine design, aligning with WHO goals for equitable infectious disease management.
×
